Pretreatment Intracerebral and Peripheral Blood Immune Responses in Vietnamese Adults with Tuberculous Meningitis: Diagnostic Value and Relationship to Disease Severity and Outcome

Tuberculous meningitis (TBM) is the most devastating form of tuberculosis. Both intracerebral and peripheral blood immune responses may be relevant to pathogenesis, diagnosis, and outcome. In this study, the relationship between pretreatment host response, disease phenotype, and outcome in Vietnamese adults with TBM was examined. Before treatment, peripheral blood IFN-γ ELISPOT responses to the Mycobacterium tuberculosis Ags ESAT-6, CFP-10, and purified protein derivative (PPD) were a poor diagnostic predictor of TBM. Cerebrospinal fluid IL-6 concentrations at presentation were independently associated with severe disease presentation, suggesting an immunological correlate of neurological damage before treatment. Surprisingly however, elevated cerebrospinal fluid inflammatory cytokines were not associated with death or disability in HIV-negative TBM patients at presentation. HIV coinfection attenuated multiple cerebrospinal fluid inflammatory indices. Low cerebrospinal fluid IFN-γ concentrations were independently associated with death in HIV-positive TBM patients, implying that IFN-γ contributes to immunity and survival. Collectively, these results reveal the effect of HIV coinfection on the pathogenesis of TBM and suggest that intracerebral immune responses, at least in HIV-negative cases, may not be as intimately associated with disease outcome as previously thought.

[1]  J. Farrar,et al.  The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. , 2005, The Journal of infectious diseases.

[2]  A. Tunkel Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.

[3]  J. Farrar,et al.  The Clinical Benefit of Adjunctive Dexamethasone in Tuberculous Meningitis Is Not Associated with Measurable Attenuation of Peripheral or Local Immune Responses1 , 2005, The Journal of Immunology.

[4]  N. H. Duc,et al.  Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. , 2005, The Journal of infectious diseases.

[5]  Ajit Lalvani,et al.  Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study , 2004, The Lancet.

[6]  Priscille Brodin,et al.  ESAT-6 proteins: protective antigens and virulence factors? , 2004, Trends in microbiology.

[7]  P. López-Saura,et al.  Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study , 2004, BMC infectious diseases.

[8]  L. Fabbri,et al.  T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. , 2004, American journal of respiratory and critical care medicine.

[9]  S. Cole,et al.  Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. , 2004, The Journal of infectious diseases.

[10]  J. Farrar,et al.  Improving the Bacteriological Diagnosis of Tuberculous Meningitis , 2004, Journal of Clinical Microbiology.

[11]  J. Farrar,et al.  Pathophysiology and prognosis in vietnamese adults with tuberculous meningitis. , 2003, The Journal of infectious diseases.

[12]  J. Deeks,et al.  Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak , 2003, The Lancet.

[13]  J. Deeks,et al.  Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells , 2001, The Lancet.

[14]  H. Vordermeier,et al.  Use of Synthetic Peptides Derived from the Antigens ESAT-6 and CFP-10 for Differential Diagnosis of Bovine Tuberculosis in Cattle , 2001, Clinical Diagnostic Laboratory Immunology.

[15]  J. Farrar,et al.  Identification of a Matrix-Degrading Phenotype in Human Tuberculosis In Vitro and In Vivo1 , 2001, The Journal of Immunology.

[16]  A. Hill,et al.  Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. , 2001, The Journal of infectious diseases.

[17]  S. Katrak,et al.  The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection , 2000, Journal of the Neurological Sciences.

[18]  I. Orme,et al.  Interleukin-6 Induces Early Gamma Interferon Production in the Infected Lung but Is Not Required for Generation of Specific Immunity to Mycobacterium tuberculosisInfection , 2000, Infection and Immunity.

[19]  R. Young,et al.  Tumor necrosis factor α is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system , 1999 .

[20]  M. Jordana,et al.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. , 1998, The Journal of clinical investigation.

[21]  V. Vullo,et al.  Cerebrospinal fluid cytokines in patients with tuberculous meningitis. , 1997, Clinical immunology and immunopathology.

[22]  W. Rom,et al.  Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol , 1997, The Lancet.

[23]  K. Olsen,et al.  Concentrations of Interferon γ, Tumor Necrosis Factor α, and Interleukin-1β in the Cerebrospinal Fluid of Children Treated for Tuberculous Meningitis , 1995 .

[24]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[25]  H. Saito Pathogenesis of tuberculous meningitis. , 1956, Acta tuberculosea Japonica.

[26]  S. J. Shane,et al.  Tuberculous meningitis: combined therapy with cortisone and antimicrobial agents. , 1953, The New England journal of medicine.

[27]  Streptomycin in Tuberculosis Trials Commitee STREPTOMYCIN treatment of tuberculous meningitis. , 1948, Lancet.

[28]  P. Klenerman,et al.  Ex vivo characterization of early secretory antigenic target 6-specific T cells at sites of active disease in pleural tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  H. Akalın,et al.  Cerebrospinal fluid interleukin-1 beta/interleukin-1 receptor antagonist balance and tumor necrosis factor-alpha concentrations in tuberculous, viral and acute bacterial meningitis. , 1994, Scandinavian journal of infectious diseases.

[30]  J. Van Snick Interleukin-6: an overview. , 1990, Annual review of immunology.

[31]  I. Cathie,et al.  Streptomycin in the Treatment of Tuberculous Meningitis , 1950 .